Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Presence of Anti–SARS-CoV-2 Antibodies Among University Student Dormitory Residents, September–November 2020
Hannah E. Segaloff(Wisconsin Department of Health Services), Hannah L. Kirking(Centers for Disease Control and Prevention), Rodel Desamu-Thorpe(Centers for Disease Control and Prevention), Dustin W. Currie(Centers for Disease Control and Prevention), Clint N. Morgan(Centers for Disease Control and Prevention), Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Patrick Remington(University of Wisconsin Health), Allen Bateman, Monique A. Foster(Centers for Disease Control and Prevention), Jake Baggott(University of Wisconsin–Madison), Glen R. Abedi(Centers for Disease Control and Prevention), Ryan P. Westergaard(University of Wisconsin–Madison), Tarah Somers(Centers for Disease Control and Prevention), Patrick Kelly(University of Wisconsin–Madison), Christopher H. Hsu(Centers for Disease Control and Prevention), J. E. Tate(Centers for Disease Control and Prevention), David Payne(Centers for Disease Control and Prevention), Devlin Cole(Wisconsin Department of Health Services), Christine C. Lee(Rensselaer Polytechnic Institute), Jeanne C. Ruff(Centers for Disease Control and Prevention), Collin Pitts(University of Wisconsin–Madison)
Cited by 18
Related Papers
Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021
|Preventing Chronic Disease|2021|370
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
|MMWR Morbidity and Mortality Weekly Report|2021|215
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
|The Lancet Infectious Diseases|2022|183
COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
|MMWR Morbidity and Mortality Weekly Report|2021|167